Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 19 小时前评分70
正文 · 原文
#ESMO26 🧬 Epsametostat (HH2853) | Phase II
🎯 Advanced epithelioid sarcoma
💊 Dual EZH1/2 inhibitor
👥 94 pts | 75 efficacy-evaluable
📈 ORR: 40% | DCR: 77.3%
⏳ mPFS: 13.1 mo | mDoR: 15.6 mo
🎯 mOS: Not reached
⚠️ G≥3 TRAEs: 39.4%
🚀 Primary endpoint met!
52 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com